Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 USD | -6.95% |
|
-7.00% | -38.82% |
Jun. 12 | Cytek Biosciences to Seek M&A | CI |
Jun. 12 | Transcript : Cytek Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-38.82% | 793M | D+ | ||
+9.99% | 189B | B- | ||
+25.98% | 150B | B- | ||
+32.78% | 113B | A- | ||
+1.98% | 65.05B | A- | ||
+14.24% | 52.83B | B+ | ||
+2.92% | 49.39B | B+ | ||
-6.37% | 38.1B | A | ||
-1.20% | 35.14B | - | ||
+22.60% | 31.2B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CTKB Stock
- Ratings Cytek Biosciences, Inc.